The present paper reviews the data of dupilumab-associated conjunctivitis and risk factors in adults with moderate-to-severe AD and other atopic diseases in dupilumab clinical trials and addresses the characteristics and treatment options available for this clinically highly relevant condition.
AD is often complicated and difficult to manage in many Asian cities and effective therapy is impeded by fallacies. In this article eleven anonymized case scenarios are described to illustrate issues associated with these fallacies. A literature review is performed and possible solutions to handle or dismiss these fallacies are discussed.
This article reviews current classes of emollients in the market, their clinical evidence in atopic dermatitis and considerations for choice of an emollient.
This review focuses on the safety and efficacy of topical calcineurin and PDE4 inhibitors for the treatment of atopic dermatitis.
